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ABSTRACT 
 
Aldehyde dehydrogenases (ALDHs) oxidize aldehydes to the corresponding carboxylic acids using 
either NAD, or NADP as a coenzyme. Aldehydes are highly reactive aliphatic, or aromatic 
molecules which play an important role in numerous physiological, pathological and 
pharmacological processes. ALDHs have been discovered in practically all organisms and there are 
multiple isoforms, with multiple subcellular localizations. More than 160 ALDH cDNAs, or genes 
have been isolated and sequenced to date from various sources, including bacteria, yeast, fungi, 
plants and animals. 
The eukaryote ALDH genes can be subdivided into several families; the human genome contains 19 
known ALDH genes, as well as many pseudogenes. Noteworthy is the fact that that elevated activity 
of various ALDH families, namely ALDH1A2, ALDH1A3, ALDH1A7, ALDH2*2, ALDH3A1, 
ALDH4A1, ALDH5A1, ALDH6, and ALDH9A1, has been observed in normal and cancer stem 
cells. Consequently, ALDH may be not only be considered a marker of these cells, but also may 
well play a functional role in terms of self-protection, differentiation and/or expansion of stem cell 
populations. 
The ALDH3 family includes enzymes able to oxidize medium-chain aliphatic and aromatic 
aldehydes, such as peroxidic and fatty aldehydes. Moreover, these enzymes also have non-catalytic 
functions, including antioxidant functions and some structural roles. The gene of the cytosolic form, 
ALDH3A1, is localized on chromosome 17 in human beings and on the 11th and 10th chromosome, 
in the mouse and rat, respectively. ALDH3A1 belongs to the phase II group of drug-metabolizing 
enzymes and is highly expressed in the stomach, lung, keratinocytes and cornea, but poorly, if at all, 
in normal liver. Cytosolic ALDH3 is induced by polycyclic aromatic hydrocarbons, or chlorinated 
compounds, such as 2, 3, 7, 8-Tetrachlorodibenzo-p-dioxin in rat liver cells and increases during 
carcinogenesis. It has been observed that this increased activity is directly correlated to the degree 
of deviation in hepatoma and lung cancer cell lines, as is the case in chemically-induced hepatoma 
in rats. High ALDH3A1 expression and activity have been correlated with cell proliferation, 
resistance against aldehydes derived from lipid peroxidation and resistance against drug toxicity, 
such as oxazaphosphorines. Indeed, cells with a high ALDH3A1 content are more resistant to the 
cytostatic and cytotoxic effect of lipidic aldehydes than are those with a low content. A reduction in 
cell proliferation can be observed when the enzyme is directly inhibited by the administration of 
synthetic specific inhibitors, antisense oligonucleotides or siRNA, or indirectly inhibited by the 
induction of PPARγ (Peroxisome Proliferator-Activated Receptor) with polyunsaturated fatty acids, 
or PPARγ transfection. Conversely, cell proliferation is stimulated by the activation of ALDH3A1, 
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whether by inhibiting PPARγ with a specific antagonist, antisense oligonucleotides, siRNA, or a 
medical device (i.e. composite polypropylene prosthesis for hernia repair) used to induce cell 
proliferation. To date, the mechanisms underlying the effects ALDH has on cell proliferation are 
not yet fully clear. A likely hypothesis is that the regulatory effect is mediated by the catabolism of 
some endogenous substrates deriving from normal cell metabolism, such as 4-hydroxynonenal, 
which have the capacity to either stimulate, or inhibit the expression of genes involved in regulating 
proliferation. 
 
 
Keywords: ALDH families; ALDH3A1; stem cells; normal and cancer cells; breast; liver; lung; 
skin; Ah gene bactery; drug resistance; cell proliferation; PPAR; polyunsaturated fatty acids; lipid 
peroxidation; 4-hydroxynonenal. 
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Introduction 
 
Aldehyde dehydrogenase (ALDH) is a family of enzymes involved in the maintenance of cellular 
homeostasis by metabolizing both endogenous and exogenous reactive compounds [1,2]. Indeed, 
they are known to modulate several cell functions, including proliferation, differentiation and 
survival, as well as the cellular response to oxidative stress. ALDHs exhibit a rather broad substrate 
specificity and many of them are able to oxidize several highly-reactive aliphatic and aromatic 
aldehydes that play an important mediating role in numerous physiological, pathological and 
pharmacological processes. Generally speaking, aldehydes derived from either exogenous, or 
endogenous precursors, may be either beneficial, or harmful to human health. Exogenous 
aldehydes, whether intermediates, or products, may derive from the metabolism of drugs (e.g. 
ethanol, cyclophosphamide, ifosfamide), or substances present in the environment (i.e. smog, 
cigarette smoke and vehicle exhaust fumes), or may even be introduced as such [1,3-6]. 
Endogenous aldehydes derive from the metabolism of amino acids, biogenic amines, vitamins, 
steroids, or lipids. Different aldehydes perform various different functions e.g. retinal is required for 
vision, whereas its oxidation product from ALDH, retinoic acid, is involved in tissue differentiation. 
Betaine, derived from oxidation of betaine aldehyde, an intermediate product of choline 
metabolism, has a crucial defence role against osmotic stress. Whilst γ-aminobutyric acid, semi-
aldehyde succinic dehydrogenase is involved in its catabolism [1,3,5,7]. Aldehydes are also potent 
electrophiles formed during oxidative stress and may interact with cellular nucleophiles, such as 
proteins and nucleic acids [8,9]. ALDHs are able to detoxify such cytotoxic and cytostatic 
aldehydes into less reactive forms [10,11]. 
By using NAD, or NADP as coenzymes, ALDHs oxidize aldehydes to their corresponding 
carboxylic acids. Although interest in the role of ALDH was initially concentrated on the 
metabolism of ethanol, where acetaldehyde is transformed into acetic acid, subsequently, the 
metabolism of other important compounds has also been examined. Since then, numerous studies 
have demonstrated the presence of ALDHs in practically all organisms, as well as in multiple 
isoforms [12-14] and their presence in the cytoplasm, nucleus, mitochondria and the endoplasmic 
reticulum. Depending on the enzyme family and subfamily, ALDH enzyme levels vary, as does 
tissue and organ distribution [3]. 
They also exhibit additional, non-enzymic functions, including the capacity to bind to some 
hormones and other small molecules, as well as that of attenuating the effect ultraviolet irradiation 
has on the cornea. Mutations in ALDH genes, that lead to a defective aldehyde metabolism, are the 
molecular basis of several diseases, including gamma-hydroxybutyric aciduria, pyridoxine-
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dependent seizures, Sjögren-Larsson syndrome and type II hyperprolinaemia and may even 
contribute to the etiology of complex diseases, including cancer and Alzheimer's disease. 
Interestingly, several ALDH enzymes appear to be markers for both normal and cancer stem cells 
[1]. More than 160 ALDH cDNAs, or genes have been isolated and sequenced from various sources 
e.g. bacteria, yeast, fungi, plant and animals [15-17] and current knowledge reports 19 putatively 
functional genes and many pseudogenes in the human genome [1]. 
 
ALDH families 
 
A total of 86 distinct cDNAs, or genes of ALDH have been cloned in eukaryotes and have been 
divided into several families, including subfamilies, showing a sequence similarity of 60 % or more 
(from http://www.aldh.org/superfamily.php) [18,19]. At present, family 1 has 11 subfamilies, 
families 3 and 5 each have 3 subfamilies, families 4, 6, 7, 8 and 9 have two subfamilies and the 
other families have one subfamily each [18,19]. Every single ALDH gene subfamily is a genetically 
segregating distinct unit, or cluster of genes, located close together in the same chromosomal 
region. For example, mouse Ahd3a1 and Ahd3a2 genes are localized in the same mapping position 
on chromosome 11 and human ALDH3A1 and ALDH3A2 are localized to the same mapping 
position on chromosome 17. To date, the human ALDH superfamily is currently known to have 19 
putatively-functional genes, clustered in 11 families and 4 subfamilies [19, 20] with distinct 
chromosomal locations. ALDH families have some specific functions such as: 
- the ALDH1 family, present especially in the cytosol of various tissues, includes enzymes able to 
oxidize retinal and aliphatic aldehydes. It also plays a role in the detoxification of peroxidic 
aldehydes produced by ultraviolet light absorption, protecting the lens of the eye [21]. Moreover, it 
exhibits high activity for oxidation of aldophosphamide and has a role in the detoxification of some 
commonly used anticancer drugs, such as oxazaphosphorines [22,23]. It has been demonstrated that 
cancer cell acquired drug resistance is associated to the transcriptional activation of ALDH1 
expression [24]; 
- the ALDH2 family codes mitochondrial ALDH, which has a high affinity for acetaldehyde and  
plays an important role in its detoxification. The greater sensitivity of oriental populations to 
alcohol is associated with a genetic deficiency of ALDH2, due to the presence of a gene 
polymorphism of the allele ALDH2*2 [6,25]; 
- the ALDH3 family contains enzymes which have a specific role in fatty and peroxidic aldehyde 
metabolism and an high ALDH3 activity is present in the cornea, stomach, liver endoplasmic 
reticulum, as well as in some cancer cells [26]; 
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- the ALDH4 family codes for a mitochondrial enzyme with high activity in the oxidation of γ-
semialdehydes [16]; 
- the ALDH5 family contains enzymes metabolizing succinic semialdehyde. Succinic 
semialdehyde dehydrogenase (SSDH) is strongly expressed in the human brain [27], where it is 
involved in γ-aminobutyric acid degradation [18]. Genetic deficiency of SSDH alters the 
metabolism of succinic semialdehyde, causing it to accumulate, leading to a variety of moderate to 
severe phenotypic neurological disorders, including mental retardation, ataxia and seizures [28]; 
- the ALDH6 family codes for the CoA-dependent methylmalonate-semialdehyde dehydrogenase 
(MMSDH). This enzyme participates in the degradation of valine and pyrimidines, causing the 
transformation of malonate and methylmalonate into acetyl- and propionyl-CoA, respectively [29]; 
- the ALDH9 family codes for enzymes involved in the metabolism of 4-aminobutyraldehyde and 
aminoaldehydes derived from polyamines and choline. Although this gene is strongly expressed in 
the early stages of embryonic brain development, it is poorly expressed in the human adult brain. 
Conversely, in adults, this enzyme is present in the liver, kidney and muscle [16]; 
- the ALDH16 family codes for an enzyme which is widely expressed in a variety of tissues, 
including bone marrow, heart, kidney and lung, even if its physiological significance and function 
still remain to be established [30]; 
- the ALDH18 family codes for a bifunctional ATP- and NAD(P)H-dependent mitochondrial 
inner membrane enzyme with both gamma-glutamyl kinase and gamma-glutamyl phosphate 
reductase activities. Traditionally known as ∆1-pyrroline-5-carboxylate synthetase, ALDH18 
catalyzes the reduction of L-glutamate to ∆1-pyrroline-5-carboxylate, a critical step in the de-novo 
biosynthesis of proline, ornithine and arginine. It is expressed at high levels in human pancreas, 
ovary, testis and kidney. Defects in ALDH18A1 lead to a variety of metabolic and neurologic 
abnormalities, including hypoprolinemia, hypoornithinemia, hypocitrullinemia, hypoargininemia 
and hyperammonemia with cataract formation, neurodegeneration and connective tissue anomalies 
[30]. 
Other families contain plant, protozoan or yeast genes [18]. The main characteristics of ALDH 
families and pathologies associated with altered expression are summarized in Table 1. 
 
ALDH families in stem cells 
 
Interestingly, it has been demonstrated that various ALDH families are strongly active in both 
normal and cancer stem cells. Therefore, ALDH may be considered a marker for these cells and 
may well play a functional role, in terms of self-protection, differentiation and/or expansion of the 
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stem cell populations. These observations have been facilitated by the possibility to assess 
functional ALDH activity in live cells by immunohistochemistry (Aldefluor). As ALDHs have a 
cross-reactivity and a relatively wide substrate spectrum, it has been possible to determine that the 
ALDH-positivity, evidenced in various types of stem cells, is not due to the expression of the same 
isoforms. Although ALDH1A1 was first indicated as a marker and characteristic feature in 
primitive human hematopoietic progenitor cells (HSCs) isolated from bone marrow and in neural 
stem cells [31,32], recent studies have reported that ALDHs (ALDH1A2, ALDH1A3, ALDH1A7, 
ALDH2*2, ALDH3A1, ALDH4A1, ALDH5A1, ALDH6A1 and ALDH9A1 [33,34]) are also 
involved, since ALDH1A1 deficiency does not alter Aldefluor positivity. It is believed that this 
heterogeneity indicates that the isoform responsible for Aldefluor activity in the case of normal cells 
depends on the type of cell and on the tissue of origin in the case of cancer cells. That is why most 
studies on ALDH and stem cells do not specify the ALDH isoform, but speak rather generically of 
ALDH. However, particularly ALDH1A1 has been identified as a marker for the isolation and 
identification of normal, or cancer stem cells, and, along with ALDH3A1, it plays a role in 
differentiation and cell proliferation [34]. 
The enzymatic activity of ALDH in HSCs is higher than in the more mature hematopoietic cells: 
lymphocytes express the lowest level, whilst immature erythroid cells express an intermediate level 
[35]. The high ALDH expression present in HSCs is associated with an enhanced repopulating 
function and cellular resistance to cytotoxic drugs. Indeed, the presence of high ALDH1A1 and 
ALDH3A1 activity makes HSCs resistant to alkylating agents, such as activated oxazaphosphorine 
(e.g. mafosfamide or 4-hydroperoxycyclophosphamide, 4-HC). By inhibiting ALDH activity with 
various inhibitors, HSCs become sensitive to these anticancer agents employed to purge resident 
tumour cells ex vivo and/or in the treatment of autologous bone marrow transplantation [36]. HSCs 
with high ALDH activity and the ability to produce long-term, multilineage hematopoietic colonies 
have been isolated, not only from bone marrow, but also from umbilical cord blood [37] and 
circulating cells [38]. In the light of their extreme brightness at ALDEFLUOR staining, cells with 
high ALDH activity have also been indicated as ALDHbri cell populations. There are between 0.5% 
and 5% of ALDHbri cells in human bone marrow, umbilical cord blood and peripheral blood stem 
cells. The most intriguing recent observation is that ALDHbri populations isolated from bone 
marrow include haematopoietic, endothelial, mesenchymal and neural progenitor cells, which are 
crucial in repair protocols for various pathological conditions, such as ischemic diseases [37]. 
As do HSCs, several other types of normal stem cells display high levels of cytosolic ALDH 
expression: neural cells [39], myogenic cells [40, 41], mammary cells [42], prostate cells [43] and 
intestinal crypt cells [44]. ALDHbri cells, isolated from dissociated murine brain tissue, are 
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multipotent, self-renewing and able to generate new neurospheres and neuroepithelial stem-like 
cells in culture, including neurons, astrocytes and glia cells. Consistent with the importance of 
ALDH in regulating proliferation, its expression is much stronger in neural embryonic tissues than 
in adult counterparts [39, 45]. A subpopulation of ALDHbriCD56+/CD34- cells possess strong 
myogenic potential in vivo upon intramuscular transplantation in normal myoblast progenitor cells, 
even if there is some heterogeneity of ALDH expression level [41]. Another study has shown that 
ALDHbri muscle cells are resistant to the cytotoxic effect of oxidative stress, a crucial aspect during 
repair processes after ischemic injury. These characteristics appear to be peculiar to human 
myogenic precursors, since in mouse, rat, rabbit and non-human primate myoblasts, ALDH is 
expressed at very low levels [40]. In mammary epithelial cells, the positivity to Aldefluor is due, in 
particular, to the high ALDH1 expression and the positive cells, which correspond to 8% of the total 
population and are able, not only to self-renew, but also to generate both luminal and myoepithelial 
cells [46]. Recent reports on benign breast biopsies state that the ALDH1 activity associated to 
EZH2, a protein involved in stem cell renewal and carcinogenesis, is a prognostic marker for the 
risk of developing cancer [47]. 
High ALDH activity, due to a strong expression of both ALDH1a1 and ALDH1a7, has been 
evidenced in central-acinar /terminal duct cells from peripheral acinar duct units in studies carried 
out on murine pancreas [48]. ALDH1-positive cells (< 5%) are mainly located at the normal crypt 
bottom in the colon and stomach [44,49]. In normal murine prostate, a cell subset expresses high 
levels of ALDH activity associated with antigens typical of prostate basal epithelium. When cells 
with low ALDH were compared to prostatic ALDH1-positive cells, there was a 2.5-fold increase in 
the formation of prostatic tissue after in vivo transplantation [43]. 
As to cancer stem cells, increased ALDH activity was first reported in acute myeloid leukaemia 
[50], subsequently, similar observations have been reported for several types of stem cells in solid 
cancers, including breast, colon, prostate, lung, liver, pancreas and ovary [34]. Recently, a close 
correlation between ALDH and metastasis formation has been evidenced in breast cancer stem cells 
(ALDH1A) [51], human prostate cancer cell lines (ALDH7A1) [52] and adenoid cystic carcinoma 
cells [53]. Although there is a small ALDHbri population in both normal stem cells and cancer stem 
cells, the latter have been shown to have higher tumourigenic properties than cancer cells with low 
ALDH [34]. Indeed, a positive statistically significant correlation was reported between the 
presence of a high percentage of ALDHbri cells and a poor survival rate [54,55]. 
Since it has been hypothesised that, in cancer, only a small number of cells have the property of 
replication, there has been a growing interest in cancer stem cells. Whilst the other cells are 
differentiated with a reduced capacity of replication. This theory is in contrast with the view that all 
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cancer cells have the capacity to enhance tumour development. The lack of chemotherapy efficacy 
observed in some cancers might be due to the presence of stem cells with a high ALDH content, 
which contributes to drug resistance by inhibiting the beneficial effects of chemotherapy. 
The use of ALDH as a marker for cancer stem cells is a particularly interesting possibility in those 
cancers where the normal tissues have a low ALDHbri content. An enhanced understanding of the 
pathways associated with ALDH1, ALDH3 and other ALDH isoforms might well facilitate the 
development of drugs able to improve the outcomes of bone marrow transplantation, regenerative 
medicine and cancer treatment. 
Among the various ALDH families involved in stem cells, only ALDH3A1, belonging to the 
ALDH3 family, will be discussed at length in this review, due to its important role in regulating 
drug resistance and cell proliferation. 
 
The ALDH3 family 
 
The ALDH3 family includes enzymes with the capacity to oxidize medium chain aliphatic and 
aromatic aldehydes, such as peroxidic and fatty aldehydes, and enzymes which have non-catalytic 
functions, including that of antioxidant functionalities [30]. Four major mammalian ALDH3 genes 
have been reported to date i.e. 
- ALDH3A1, which encodes the cytosolic form highly expressed in some normal tissues e.g. the 
stomach, lung, keratinocytes and cornea, which is poorly expressed, if at all, in normal liver. It has a 
UV filter function in the cornea [56,57] and is highly expressed in some human and rat tumours 
(hepatoma, breast and lung cancer), as well as in stem cells [58-60]; 
- ALDH3A2, which encodes the liver microsomal fatty aldehyde dehydrogenase [61,62] and has 
been implicated in the Sjögren-Larsson syndrome [63]; 
- ALDH3B1, which encodes the human lung, prostate and kidney cytosolic ALDH [64,65]. 
Recent studies have linked a single nucleotide polymorphism at the ALDH3B1 locus to the 
development of paranoid schizophrenia [66,67]; 
- ALDH3B2, which encodes the human salivary gland and placental ALDH [68]. 
The ALDH3A1 gene is located on chromosome 17 in human beings and on chromosomes 11 and 10 
in the mouse and rat respectively. It belongs to the drug-metabolizing enzymes of the phase II 
group. In the liver, ALDH3A1 is a member of the Ah gene battery, including the Cytochrome P-450-
1 family members, Glutathione-S-TransferaseA2, NAD(P)H:quinone acceptor oxidoreductase and 
UDP-glucuronosyltransferase 1A6 (Figure 1). These genes are modulated by the presence of 
positive, or negative regulatory regions. Their activation takes place through the aryl hydrocarbon 
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(Ah) receptor, which is a transcription factor binding to the consensus sequence, Ah responsive 
element (AhRE) [69,70]. An important class of environmental pollutants that have a wide range of 
toxic and carcinogenic effects i.e. polycyclic aromatic hydrocarbons (PAH), or chlorinated 
compounds e.g. TCDD (2,3,7,8-Tetrachlorodibenzo-p-dioxin), which are ligands for the Ah receptor 
[71]. Two sequences that have significant similarity with the AhRE core have been observed in the 
5'-flanking region of the ALDH3A1 gene [72]. As well as positive regulation through AhRE 
sequences, the 5'-flanking region of ALDH3A1 contains also at least two negative regulatory 
regions which repress promoter activity and the TCDD-response, respectively. These negative 
regions are bound by the Nuclear Factor 1 (NF-1)-like transcription factors and/or unique proteins. 
The 5' flanking region is responsible for the regulation of the constitutive expression of ALDH3A1 
in many tissues [72]. 
There is also activation of ALDH3A1 by PAH in human MCF-10A mammary epithelial cells, when 
treated with benzo(a)pyrene (BaP), a known human carcinogen. BaP is metabolized by several 
pathways, some of which have bioactivation properties, whilst others have detoxification properties. 
BaP-quinones, formed via cytochrome P450 and peroxidase dependent pathways, have significant 
growth promoting and anti-apoptotic properties and activate phase 2 enzyme genes, including 
ALDH3A1. An increased ALDH3A1 activity in human mammary epithelial cells is associated with 
increased cell growth and survival, which may play important roles in tumour promotion. [73]. 
Moreover, ALDH3A1 levels are induced, not only by environmental contaminants, but also by 
polyphenol, e.g. catechol [74]. Since the alimentary tract and lungs are the major "ports of entry" 
for dietary and environment substances, it is feasible to presume that these substances may induce 
high levels of ALDH3A1 at these sites. 
 
ALDH3A1 in some non-tumoural and tumoural tissues 
THE BREAST 
It has been observed that ALDH3 levels vary widely in normal, malignant primary and metastatic 
breast tissue samples. Although the average enzyme levels in the malignant breast tissue samples 
were significantly higher than those in normal breast tissue samples, the average ALDH3 level in 
metastatic breast tumour samples were not significantly higher than those in primary breast tumour 
samples. Cellular levels of ALDH3 in the malignant breast tissue samples appeared to be directly 
related to those present in the corresponding normal tissue [75]. A recent study has demonstrated 
that ALDH3A1 is present in higher quantities in breast cancer fibroblasts (BCFs) than in normal 
mammary fibroblasts (NMFs) [76]. This study investigated the regulatory effects of BCFs vs NMFs 
on mammosphere formation and stem-cell-related gene expression, in MCF-7 breast cancer cells. 
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The cells were cultured in suspension to generate primary and secondary mammospheres. When 
MCF-7 cells were co-cultured with BCFs, there was a decrease in the mammosphere formation 
time, whilst the volume of the mammospheres increased with a higher mammosphere-forming 
efficiency than was observed in presence of NMFs. Both the BCF and NMF groups showed 
enhanced gene expression of ALDH3A1 (fold-change, 5.23 and 1.85, respectively). Cancer 
fibroblast cells have the capacity to enhance mammosphere-forming efficiency and up-regulate 
stem cell-related gene expression in breast cancer cells [76]. ALDH3A1 is upregulated in cultured 
breast cancer cells by exposure to Ah receptor ligands, e.g. 3-methylcholanthrene, or to 
electrophiles, such as catechol. The 3-methylcholanthrene-mediated upregulation, via transient 
transactivation of xenobiotic responsive element (XRE), is apparently estrogen receptor (ER)-
dependent. Whilst, conversely, catechol-mediated up-regulation takes place via transient 
transactivation of an electrophile responsive element and is ER-independent [77]. 
 
THE CORNEA 
The mammalian cornea, located at the anterior surface of the eye, is an avascular tissue that has the 
function of a protective barrier between the environment and the internal ocular structures. Indeed, 
one of the primary sources of environmental stress for the cornea is solar radiation, in particular, 
those in the ultraviolet (UV)-range. The concomitant exposure to UV-radiation and molecular 
oxygen trigger an excessive production of reactive oxygen species (ROS), which, in turn, lead to 
substantial oxidative stress and subsequent corneal damage [78]. The cornea has developed several 
antioxidants and repair systems so as to defend itself against this dangerous condition [79]. It has 
been clearly shown that ALDH3A1 plays a crucial role in corneal defence [80]. As its steady-state 
concentration in the cornea is over and above what would be simply needed for metabolism, it has 
been hypothesized that the enzyme has additional protective roles: 1) direct absorption of UV-
radiation; 2) an antioxidant function, either directly by the scavenging of free radicals, or, indirectly, 
by the production of NADPH, 3) maintaining the refractive and transparent properties of the cornea, 
as a corneal crystalline, and 4) a chaperone-like activity. The hypothesis that direct absorption of 
UV-radiation by ALDH3A1 protects corneal proteins and, consequently, leads to the inactivation 
and formation of soluble aggregates of ALDH3A1, has been further supported by experimental 
evidence. In C57BL/6J inbred mice, UV-radiation exposure caused an 85% reduction in ALDH3A1 
activity, whereas other metabolic enzyme activities remained intact [81]. Similarly, a large excess 
of ALDH3A1 in vitro reduced the UV-induced inactivation of glucose-6-phosphate dehydrogenase 
[82]. The inactivation of ALDH3A1 by UV to preserve other corneal elements has been termed a 
“suicide response” [80,83]. 
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Since ALDH3A1 is the primary enzyme responsible for the detoxification of aldehydes in the 
cornea [57], it might be reasonable to suppose that the loss of ALDH3A1 activity may severely 
impair the ability this tissue has to reduce and eliminate aldehydes, especially under conditions of 
oxidative stress. However, this is not the case, as the cornea shows an abundant expression of 
ALDH3A1 [84,85], which is combined with the enzyme’s broad range of substrate specificity [86]. 
It is likely that both these factors make for the induction of aldehyde metabolisms, also in the 
presence of substantial ALDH3A1 inactivation. Therefore, it may be that, even in the presence of 
inactivation of ALDH3A1 by UV and other stresses, the cornea is not completely defenceless 
against toxic aldehydes [87]. 
 
THE LIVER 
Cytosolic ALDH3A1 is poorly expressed, if at all, in liver cells, unlike the cytosolic ALDH1, 
which, in normal human liver, contributes to the detoxification of various exogenous and 
endogenous, aliphatic and aromatic aldehydes, with various chain lengths. ALDH3A1 is induced by 
PAH, or chlorinated compounds in normal rat liver [71] and its expression increases in direct 
correlation with the degree of deviation in hepatoma cells, or chemically-induced hepatoma [88,89]. 
Table 2 shows the levels of ALDH3A1 activity: there is a higher activity in hepatoma cells than in 
hepatocytes, a higher activity in hepatoma compared to neoplastic nodules during chemically-
induced hepatocarcinogenesis and a higher activity in the more deviated JM2 and HTC hepatoma 
cell lines compared to the less deviated 7777 and MH1C1 hepatoma cell lines [88]. 
ALDH3A1 activity is higher in the more deviated SK-HEP-1 hepatoma cells in human beings, 
compared to less deviated HepG2 (Table 2). Examination of hepatocellular carcinoma tissues from 
patients with this form of cancer showed that approximately 50% had a high ALDH3 expression as 
a result of the expression, or activation, of nuclear proteins reacting to the ALDH3 promoter region. 
Two of these nuclear proteins, along with 35 and 16 kDa, have been determined in ALDH3-positive 
hepatoma cell lines and cancerous liver, but not in ALDH3-negative normal liver tissues. DNaseI 
footprint analysis identified two protective regions within the ALDH3 promoter. The first protected 
region has one putative CCAAT-box and one putative Sp1-site. The second protected region 
contains a putative HiNF-A binding sequence [90]. 
 
THE LUNG 
ALDH3A1, as is ALDH1A1, is important in both alveolar pneumocyte physiology and lung 
cancers. In the lung, ALDH3A1 has the function of metabolizing aldehydes, which may occur 
naturally in the environment as a breakdown product of xenobiotics, or may derive from an 
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endogenous metabolism. It has been shown that cigarette smoking alone suffices to make the 
ALDH3A1 expression rise in normal pneumocytes. Indeed, its expression was higher in the normal 
pneumocytes of smokers than in those of non-smokers. Carcinogenic compounds found in cigarette 
smoke, which include aldehydes, upregulate ALDH isozymes in lung tissue, as reported by a study 
on lung cancer samples taken from patients with, or without, a history of cigarette smoking [4]. 
There is a high ALDH3A1 expression in some non-small cell lung cancer cell lines, such as A549 
cells, as well as in specimens from lung cancer patients [4,10,91,92]. The expression of the enzyme 
gradually increases during the transition from normal to atypical pneumocytes, carcinoma in situ, 
and then adenocarcinoma. These observations show that an elevated expression of the enzyme is 
related to the malignant transformation. Immunohistochemical staining for ALDH3A1 on 
specimens from control patients without lung cancer and from patients with one of the primary lung 
cancers, i.e. squamous cell cancer (SCCA), adenocarcinoma, or small-cell lung cancer (SCLC), 
indicated a significantly higher level of ALDH3A1 expression in SCCA and adenocarcinoma than 
in SCLC [4]. A similar pattern was also evidenced for ALDH1A1 expression [4]. 
The fact that SCCA and adenocarcinoma express ALDH3A1 takes on importance in the treatment 
phase, as the presence of this enzyme has been associated with resistance to oxazaphosphorines, 
such as cyclophosphamide [93]. Moreover, it has been shown that selectively knocking down RNA 
expression of ALDH3A1 in A549 cells leads to an increased susceptibility to cyclophosphamide 
[94]. Indeed, decreasing ALDH3A1 with arachidonic acid, A549 cells become more susceptible to 
the cytostatic effect of lipid peroxidation aldehydes [10]. 
 
OTHER NORMAL TISSUES AND TUMOURS 
Very few papers were found on the expression of ALDH3A1 in animal and human skin cells. One 
reported that ALDH3A1 was constitutively expressed in the skin of mouse and rat, but not in that of 
the guinea-pig. It also reported that immunohistochemistry staining showed the localization of 
ALDH3A1 predominantly in the epidermis, sebaceous glands and hair follicles of mouse and rat 
skin [95]. As to human skin, one paper reports that ALDH3 enzyme is expressed, constitutively, in 
three different anatomical regions of human skin (foreskin, breast, abdomen) and may play a 
significant role in the metabolism of endogenous or xenobiotic aldehydes [96]. Another paper 
reported that the human keratinocytes NCTC 2544 display a high ALDH3A1 expression [97]. 
High ALDH3A1 levels have been observed in certain other human tissues and cells e.g. normal 
stomach mucosa, parotid gland tumours, colon cancer cell lines and in some, but not all, colonic 
adenocarcinoma specimens [98].The two DNA binding proteins, discovered in liver cancers and 
responsible for increased ALDH3A1 expression, are not found in normal stomach tissues, or in 
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stomach carcinoma KATO III cells [90]. The high ALDH3A1 levels in gastrointestinal cancers may 
be one reason why cyclophosphamide has poor clinical efficacy in this type of cancer [99]. 
 
ALDH3A1 as cytoprotective enzyme 
The effect the presence of high ALDH3A1 activity has on non tumoural cells differs from the effect 
it has on tumoural cells. Indeed high ALDH3A1 activity protects healthy cells from the effect of 
some carcinogens, whilst it contributes to the onset of drug resistance in tumoural cells. 
 
PROTECTION FROM CARCINOGEN EFFECT 
It has recently been suggested that ALDH3A1, as other detoxifying and antioxidant enzymes, can 
also be used as biomarkers, to determine whether the dose of chemopreventive agent administered 
reaches the target cells and upregulates genes and proteins so as to protect cells from endogenous 
and exogenous carcinogens. Among natural chemopreventive agents, sulforaphane, an 
isothiocyanate found in cruciferous vegetables, with particularly high levels in broccoli sprouts is 
known to protect cells from damage, by inducing detoxication and antioxidant enzymes. That is 
why it is considered to be an attractive chemopreventive agent, because sulforaphane is safe and is 
easily extracted from broccoli sprouts. Treating MCF10A and MCF12A cells with sulforaphane 
induced marked upregulation of cytoprotective enzymes, including ALDH3A1 [100]. 
 
DRUG RESISTANCE 
The increased ALDH expression observed in tumour cells is one of reasons why they are resistant 
to drug toxicity and their consequent poor response to antitumoural drugs. In particular, ALDH is 
responsible for tumour resistance against alkylating agents, such as oxazaphosphorines (eg. 4-HC) 
and to lipid peroxidation products. Some anti-neoplastic agents have been shown to produce 
oxidative stress in tumours during cancer chemotherapy, with consequent lipid peroxidation and 
generation of aldehydes. The direct correlation between ALDH3A1 activity and resistance to 
oxazaphosphorines has been evidenced in vitro: culturing human tumour cells in the presence of 
high concentrations of these agents, within a single period of 30-60 minutes, increased ALDH3A1 
activity, making the cells stably insensitive to oxazaphosphorines [101]. 
This correlation has been also confirmed transfecting rat ALDH3 into human MCF-7 cells, 
conferring oxazaphosphorines-specific resistance. The resistance was reversed by pretreatment with 
the ALDH3 inhibitor diethylaminobenzaldehyde [75]. Analysis of the metabolites formed by 
ALDH3 from cyclophosphamide has provided new and full evidence to support the hypothesis that 
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aldophosphamide oxidation is the primary mechanism of oxazaphosphorine-specific resistance 
conferred by this isoenzyme.[102]. 
In human beings, it has been reported that interindividual variation in ALDH3 and ALDH1 activity 
in breast cancer could contribute to the extremely varied clinical resistance to 4-HC, which is a 
mainstay of chemotherapeutic regimens used to treat breast cancers [75,103]. Given the wide range 
of ALDH3 levels found in malignant breast tissues, the measurement of ALDH level in normal 
breast tissue and/or primary breast malignancies, prior to the initiation of chemotherapy, may well 
be of value in predicting the therapeutic potential, or lack thereof, of 4-HC in treating metastatic 
breast cancer, thus providing a rational basis for the design of individualized therapeutic regimens 
when treating this disease. 
Since ALDH3A1 is crucial in determining sensitivity to oxazaphosphorines, it is possible to pursue 
clinical strategies that raise the sensitivity of tumour cells to oxazaphosphorines, by inhibiting its 
synthesis, or decreasing the sensitivity of vulnerable and essential normal cells to these drugs, e.g., 
pluripotent haematopoietic cells, by transferring the ALDH3A1 gene [101]. Moreover, ALDH3A1 is 
one of the downstream genes of the metastasis gene Metadherin (MTDH) involved in multi-drug 
chemoresistance. MTDH is a downstream mediator of the transforming activity of Ha-Ras and c-
Myc and, as it regulates several crucial aspects of tumour progression, it has an important role in the 
carcinogenesis process including transformation, evasion of apoptosis, invasion, metastasis and 
chemoresistance. MTDH is overexpressed in more than 40% of breast-cancer patients and is 
associated with poor clinical outcomes [104]. 
It has been reported that MTDH knockdown represses ALDH3A1 expression and induces 
chemosensitization. To further investigate the functional importance of ALDH3A1 in MTDH-
mediated chemoresistance, LM2 cell line was engineered to knockdown ALDH3A1. This resulted 
in LM2 cells being more sensitive to the chemotherapeutic agents, paclitaxel, doxorubicin and 4-
HC. Whilst restoring ALDH3A1 expression made LM2 cells resistant to these agents again [104]. 
Therefore, ALDH3A1 plays a role in broad-spectrum chemoresistance [104]. Moreover, it may also 
contribute to increasing the chemoresistance of cancer stem cells [46,105]. 
 
ALDH3A1 and cell proliferation 
The content and activity of ALDH3A1 is directly correlated to cell proliferation. This may be 
demonstrated in two ways: 1) by inhibiting or 2) by activating ALDH3A1. These approaches, not 
only show the direct correlation between ALDH3A1 and proliferation, but may also be useful in 
decreasing the cell proliferation of tumour cells, stimulating cell proliferation in normal cells during 
tissue regeneration, or in increasing cornea protection from UV-radiation damage. The close 
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relationship between ALDH3A1 and proliferation has also been confirmed by studies that detected 
high expression levels in both normal and cancer stem cells, including the aforementioned studies. 
 
1) INHIBITION: 
ALDH3A1 can be directly inhibited by the administration of synthetic specific inhibitors, antisense 
oligonucleotides, or siRNA to the cells. Moreover, indirect inhibition can be obtained through the 
activation of the peroxisome proliferator-activated receptor (PPAR)γ by administering synthetic, or 
natural ligands (clofibrate or polyunsaturated fatty acids), or via PPARγ transfection. Inhibiting 
ALDH3A1 with specific inhibitors, such as tetraethylthiuram disulfide (disulfiram), 
diethylaminobenzaldehyde, or 4-amino-4-methyl-pent-2-ynthioic acid, S-methyl ester (ampal 
thiolester) and some of its derivatives, including dimethyl ampal thiolester (DIMATE) and 
morpholino ampal thiolester (MATE), has a significant inhibitory effect on cancer cell proliferation. 
These specific inhibitors have been tested on several cancer cell lines, such as A549 and H522 lung 
cancer cells, glioblastoma U251 cells, HeLa cells, L1210 cells, hepatoma JM2 and 7777 cells 
[92,106-109]. Importantly, inhibition of enzyme activity preceded the inhibition of cell growth. 
Human prostate epithelial normal cells (HPENC) and human prostate epithelial cancer cells 
(DU145) were also used to investigate DIMATE and MATE more thoroughly for selectivity and 
growth-inhibitory activity. Unequivocal evidence was obtained, showing that both compounds are 
reversible growth inhibitors of HPENC, but irreversible growth inhibitors of DU145. ALDH3A1 is 
inhibited to the same extent by both compounds. Growth inhibition of DU145 takes place through 
the induction of apoptosis. [110]. The use of antisense oligonucleotides against ALDH3A1 
completely inhibits ALDH3A1 expression and consequently decreases cell proliferation, without, 
however, affecting cell viability [107]. 
The knock-down of ALDH3A1 in lung H522 and A549 cancer cell lines by siRNA, abolishes up to 
95% of ALDH3A1 activity, leading to a significant reducing in both the growth rate and cell 
motility and migration [97]. The indirect inhibition of ALDH3A1 and, consequently, the inhibition 
of cell proliferation, can be achieved via increased PPAR expression: administration of PPAR 
ligands and PPAR transfection both reduce ALDH3A1content as well as inhibiting cell 
proliferation. 
PPARs are transcription factors belonging to the family of ligand-inducible nuclear receptors. They 
form heterodimers with the retinoid X receptors and bind to a DNA sequence named “PPRE” 
(Peroxisome Proliferator Response Element), two short hexameric sequence motifs corresponding 
to, or closely related to, 5’-aggtca-3’, with a space of one nucleotide. Their transcriptional activity is 
modulated by co-repressors and co-activators. The activation of PPARγ seems to reduce the 
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expression of ALDH3A1 through the inhibition of NFκB or AP-1 binding activity [10,91], or by 
binding to the putative PPRE present in the introns 1 and 11 of ALDH3A1 (data submitted for 
publication). 
When JM2 rat hepatoma cells were treating with clofibrate, a hypolipidemic drug and synthetic 
PPAR ligand, induced PPARγ, decreased ALDH3A1 expression and inhibited cell growth. The 
blocking of PPARγ with antisense oligonucleotides prevented the inhibitory effect of clofibrate on 
cell proliferation and ALDH3A1 expression [111]. Similar results have been obtained treating rat 
hepatoma cells and human lung tumour cells with polyunsaturated fatty acids, such as arachidonic 
acid and docosaexaenoic acid, natural ligands of PPARs [10,91,112]. The inhibition of cell 
proliferation by polyunsaturated fatty acids is inversely related to the ALDH3A1 content, as 
evidenced in Figure 2: as 7777 hepatoma cells have a low ALDH3A1 content, they are more 
susceptible to the arachidonic acid effect than are JM2 hepatoma cells, which have a high content of 
this enzyme. PPARγ transfection in human lung cancer cells and normal keratinocytes also 
confirmed the correlation with this receptor, ALDH3A1 and cell proliferation: high levels of 
PPARγ mRNA and protein due to PPARγ transfection decreased ALDH3A1 and inhibited cell 
proliferation (Figure 3) [97]. 
 
2) ACTIVATION: 
ALDH3A1 can be activated by inhibiting PPARγ with specific antagonists, antisense 
oligonucleotides (AS-ODN), siRNA, or by using medical device for tissue regeneration (composite 
polypropylene prosthesis for hernia repair). The antagonist GW9662 prevents the arachidonic acid-
mediated reduction of ALDH3A1 expression as it prevents the growth inhibition of A549 cells [10]. 
Two other approaches to increase PPARγ-dependent ALDH expression in rat hepatoma and human 
normal keratinocytes are AS-ODN and siRNA against PPARγ. Both techniques decrease PPARγ, 
whilst, at the same time, increasing both ALDH3A1 and cell proliferation [97,111]. 
To further examine the physiological roles of PPARγ and ALDH3A1 in cell proliferation, changes 
in their expression were examined in a model of tissue regeneration. To this aim, human 
keratinocytes were grown on a composite polypropylene prosthesis for hernia repair. The prosthesis 
acts as a scaffold where seeded cells can migrate and grow [113,114]. There was a higher 
percentage of cell growth on the prosthesis than when the same number of cells was grown without 
the prosthesis. At 6 post-cell seeding days, there was an 8.2 increase in the number of cells counted 
at 3 days on the prosthesis, whereas, without the support of the prosthesis, there was only a 3.1 
increase. At the same time, ALDH3A1 protein content increased during the experiment, while 
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PPARγ protein decreased (Figure 4). Further experiments are ongoing to investigate whether this 
protocol may be suitable for clinical application to improve tissue repair and regeneration. 
 
How does ALDH3A1 inhibition reduce cell proliferation? 
 
Although the mechanisms through which ALDH3A1 influences cell proliferation have not yet been 
fully understood, it is likely that they include the modulation of the genes involved in regulating 
transcription, cell growth, differentiation and apoptosis and/or the effects of the products of lipid 
peroxidation, which have the ability to modulate the gene expression. 
 
Gene modulation 
Since ALDH3A1 is highly expressed in pathological specimens from patients with primary non-
small-cell lung carcinoma (NSCLC) [85], studies have been carried out on lung cancer A549 cells 
to investigate into the mechanisms that make ALDH activity so important in cell homeostasis and 
cancer transformation. Both cell growth and proliferation are significantly affected when 
ALDH3A1 activity is reduced by siRNA, or inhibitors, possibly due to the effect they have on a 
wide spectrum of genes that have different biological roles in cells. These genes include CCL20, 
GPR37, DDX3Y, ID4, GPC6, RPS4Y1, EIF1AY, and HMGA2, and are involved in transcription 
regulation, cell growth, differentiation and apoptosis [92,115,116]. Microarray results show a high 
RPS4Y1 and CCL20 expression in A549 cells, whilst there is a weaker expression of the other 5 
genes. HMGA2 is reported to be overexpressed in lung cancer and to have an inverse correlation 
with survival [116]. It is located on chromosome 12q13-15 and clinically-relevant chromosome 12 
abnormalities have been reported among the frequent chromosomal abnormalities described in 
NSCLC [117,118]. The largest cluster of the genes affected by ALDH knock-down is on 
chromosome 12 and three of them are located on the Y chromosome. Deletion of the Y 
chromosome is one of the frequent abnormalities reported in NSCLC and is associated with 
malignant transformation and the development of lung cancer [119,120]. Therefore, these genes are 
good candidates for further investigation with the aim of defining which gene networks in the 
ALDH isozymes play important roles in cancer biology [92]. 
 
Lipid peroxidation 
ALDH3A1 also has a fundamental role in the metabolism of aldehydes derived from lipid 
peroxidation, such as toxic medium-chain alkanals, alkenals and 4-hydroxyalkenals. Lipid 
peroxidation is a consequence of oxidative stress exerted on polyunsaturated fatty acids and leads to 
the formation of reactive by-products such as lipid hydroperoxides and aldehydes. There are several 
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factors able to induce oxidative stress, including the metabolism of xenobiotics, exposure to UV-
radiation, or exposure to pro-oxidant agents e.g. ADP plus iron, or ascorbate plus iron [121,122]. 
Human ALDH3A1 demonstrated high substrate specificity for medium-chain (6 carbons and more) 
saturated and unsaturated aldehydes, including 4-hydroxy-2-nonenal (HNE), which are generated 
by the peroxidation of cellular lipids. Short-chain aliphatic aldehydes, such as acetaldehyde, 
propionaldehyde and malondialdehyde, were found to be very poor substrates for human 
ALDH3A1. HNE is the most reactive and cytotoxic of the aldehydeic byproducts of lipid 
peroxidation [123]. This aldehyde has been shown to have a variety of effects on biological 
systems, more often than not resulting in the inhibition of cell proliferation and/or cytotoxicity. For 
example, it induces glutathione depletion [124], inhibits DNA and RNA synthesis [125] and 
mitochondrial respiration [126] and induces morphological changes [127]. The effects of HNE, as 
those of other aldehydes, are correlated, not only with the extent of lipid peroxidation, but also with 
the enzyme metabolizing aldehyde activity. These include ALDH3A1, which, as aforementioned, is 
highly expressed in some normal and tumoural cells [5,88,89,128,129]. An ALDH3A1 increase 
makes both normal and tumour cells resistant to lipid peroxidation byproducts [88]. JM2 rat 
hepatoma cells with high ALDH3A1 content are more resistant to the cytostatic and cytotoxic 
effects of HNE than are 7777 rat hepatoma cells, as shown by the colony formation efficiency and 
viability after HNE treatment. The lower susceptibility of JM2 cells, due to their high ALDH3A1 
activity, is confirmed by the marked capability these cells have in removing aldehyde. 
Human lung tumour A549 cells, which express high levels of ALDH3A1 protein, were significantly 
less susceptible to the antiproliferative effects of HNE than were human hepatoma HepG2 or SK-
HEP-1 cells which have lower ALDH3A1 expression (Figure 5) [10]. Expression of ALDH3A1, by 
stable transfection in V79 hamster fibroblasts, conferred a high level of protection against growth 
inhibition by the medium-chain length aldehyde substrates, including hexanal, trans-2-hexenal, 
trans-2-octenal, trans-2-nonenal, and HNE. This was reflected in the parallel ability ALDH3A1 has 
to prevent these aldehydes causing the depletion of glutathione. The potent HNE induction of 
apoptosis was completely blocked by ALDH3A1 expression in both V79 cells and RAW 264.7 
murine macrophages, consistent with the observed total prevention of HNE-protein adduct 
formation [130]. 
One of the proposed functions for ALDH3A1 is the detoxification of aldehydes formed during UV-
induced lipid peroxidation, such as in the human cornea, where immunohistochemistry revealed 
ALDH3A1 expression in epithelial cells and stromal keratocytes [131]. This protective role 
ALDH3A1 plays against HNE was demonstrated by stably transfecting human ALDH3A1 in a 
human corneal epithelial cell line lacking endogenous enzyme. Cells transfected with ALDH3A1 
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were more resistant to HNE-induced apoptosis than were mock-transfected cells. It was also 
reported that ALDH3A1 expression prevented 4-HNE-induced protein adduct formation in the 
cornea [132]. As a whole, the data suggest that ALDH3A1 is a regulatory element of the cellular 
defence system that plays a protective role against HNE, which arises from oxidative stress induced 
by several factors, such as UV radiation and PUFAs. 
 
Conclusions 
 
Not only has the close correlation between ALDH expression and cell proliferation been evidenced 
in both normal and cancer cells, but it has more recently been confirmed by studies on normal and 
cancer stem cells. Among the human ALDH isoenzymes, ALDH3A1 plays an important role in 
metabolizing the aldehydes derived from lipid peroxidation, favouring both a reduction in the 
cytostatic effects these compounds have and cell proliferation. Moreover, its marked expression in 
cancer cells, like that of ALDH1A1, confers resistance against antitumoural drugs. In the light of 
the fact that ALDH controls several cell functions, it seems important to stimulate a positive, or 
negative modulation of its expression, so as to provide “tailor made” clinical strategies for several 
pathological conditions that require the induction (tissue regeneration), or inhibition (cancer) of cell 
proliferation. These clinical strategies could be achieved by the use of specific inhibitors, antisense 
oligonucleotides and siRNA, which cause negative ALDH regulation, or either by activating, or 
inhibiting the nuclear receptor PPARγ, which determines negative, or positive ALDH modulation. 
Its expression is indirectly regulated by PPARγ through the inhibition of NFkB and AP-1 binding 
activity. Moreover, putative PPRE sequences have been found in the ALDH gene. The modulation 
of ALDH3 may play a key role in the regulation of the growth and differentiation of both normal 
and cancer cells, also influencing some aspects of the cancer phenotype i.e. drug resistance and lipid 
peroxidation products. 
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FIGURE LEGENDS 
 
Figure 1. 
Ah gene bactery. 
 
Figure 2. 
The effect arachidonic acid enrichment has on growth in rat hepatoma cell lines. 
Hepatoma cells lines (7777 and JM2) were incubated in the presence of 60 µM arachidonic acid and 
exposed to 4 doses of ascorbate/FeSO4 (500 µM/100 µM) after 24 hours, administered at 12 hour 
intervals. The cells were harvested at the following time intervals: 
day 1: 24 hours after arachidonic acid enrichment; 
day 3: 12 hours after the fourth dose of ascorbate/FeSO4. 
Data are the averages ± SD of 6 experiments. For each cell line, averages with different letters 
differ statistically (p<0.05) from one another as determined by variance analysis followed by post 
hoc Newman–Keuls analysis. 
C, control cells; ARA, cells treated with arachidonic acid and exposed to 4 doses of 
ascorbate/FeSO4. 
 
Figure 3. 
The effect transfecting cells with pSG5 vector containing PPARγ has on cell proliferation and 
PPARγ and ALDH3A1 protein content. 
Human lung tumour cells (A549) and normal keratinocytes (NCTC 2544) were transfected with 3, 
or 5 µg pSG5 vector containing PPARγ (γ3, γ5, respectively), or pSV-β-galactosidase (C) and 
harvested at 24, or 48 hours for cell count and Western blot analysis. 
Panel A: data are averages ± S.D. from 3 experiments. For each type of cell and for 24, or 48 h, 
averages with different letters have a statistically significant difference from one another (p < 0.05) 
as determined by analysis of variance followed by post hoc Newman–Keuls analysis. 
Panel B:, the polyclonal antibody used recognized both isoforms PPARγ1 and γ2. The densitometry 
value given for each protein is referred to the corresponding β-actin value and expressed by 
arbitrarily normalizing the control value as 100. 
 
Figure 4 
ALDH3A1 and PPARγ protein content in human normal keratinocytes (NCTC 2544 cells) seeded 
on a composite prosthesis, a model for tissue repair. 
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The cells were then harvested at 3 and 6 days after cell seeding. For each protein, the data are 
densitometry values normalized to the corresponding β-actin value and referred to their respective 
control values, taken as 100. 
C, cells seeded without prosthesis; prosthesis, cells seeded on the prosthesis. 
 
Figure 5 
The effect exogenously added HNE has on cell proliferation. 
Human lung (A549) and liver (SK-HEP-1, HepG2) tumour cells were exposed for 48 hours to 
different concentrations of HNE. 
Data are averages ±S.D. from 3 experiments. For each cell line, averages with different letters have 
a statistically significant difference (p<0.05) from one another, as determined by variance analysis 
followed by post hoc Newman–Keuls analysis. 
